Assouline, S., Bartlett, N., Sehn, L., Giri, P., Kuruvilla, J., Schuster, S., Yoon, S., Fay, K., Hess, G., Dreyling, M., Gutierrez, N., Cybulski, E., Sabalvaro, F., Peneul, E., Tracy, S., Kuruvilla, D., Chen, J., Wiebking, V., Wei, M. C., Budde, E. (2025). Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study. Blood. https://doi.org/10.1182/blood-2025-5353